ONIVYDE - New treatment option for better survival in patients with metastatic pancreatic adenocarcinoma
2021
Abstract
Pancreatic carcinoma is a disease with the worst outcomes across all malignancies. Nevertheless, in the last few years, there is progress in survival due to new effective combined regimens in first line setting.
After progression on first line, the treatment options are limited and moreover, there are studies showing us contradictory results. Study, which showed an improvement in survival in patients progressing on first line with gemcitabine, or gemcitabine-based therapy is a NAPOLI-1 study.
This article summarizes main findings from this study. There are also presented data from other studies, confirming benefit of this new treatment in long term follow-up and in distinct subgroups.